Search research articles
Contact Us
Filters
Showing results (141-150 of 217) with videos related to
Page
of 22
Sort By:
Haematologica
|
December 15, 2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, et al.
Blood Cancer Journal
|
January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia
|
July 21, 2023
Prognosis of IGLV3-21<sup>R110</sup> chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
Paul J Hengeveld, Hendrik Veelken, Cornelis A M van Bergen, et al.
International Journal of Cancer
|
April 11, 2022
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
Nathalie I Bouwer, Tessa G Steenbruggen, Hánah N Rier, et al.
Blood Advances
|
December 16, 2018
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Arnon P Kater, Sabina Kersting, Yvette van Norden, et al.
JAMA Surgery
|
July 31, 2024
Enhanced Recovery After Surgery (ERAS) Society Recommendations for Neonatal Perioperative Care
Mercedes Pilkington, Gregg Nelson, Brandon Pentz, et al.
The Journal of Pathology. Clinical Research
|
August 28, 2020
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation
Paul G Kemps, Konnie M Hebeda, Steven T Pals, et al.
Blood
|
September 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, et al.
Cancer Immunology Research
|
November 12, 2020
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies
Iris de Weerdt, Roeland Lameris, George L Scheffer, et al.
Page
of 22
Search research articles
Search
Showing results (141-150 of 217) with videos related to
Sort By:
Page
of 22
Haematologica
|
December 15, 2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, et al.
Blood Cancer Journal
|
January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia
|
July 21, 2023
Prognosis of IGLV3-21<sup>R110</sup> chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
Paul J Hengeveld, Hendrik Veelken, Cornelis A M van Bergen, et al.
International Journal of Cancer
|
April 11, 2022
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
Nathalie I Bouwer, Tessa G Steenbruggen, Hánah N Rier, et al.
Blood Advances
|
December 16, 2018
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Arnon P Kater, Sabina Kersting, Yvette van Norden, et al.
JAMA Surgery
|
July 31, 2024
Enhanced Recovery After Surgery (ERAS) Society Recommendations for Neonatal Perioperative Care
Mercedes Pilkington, Gregg Nelson, Brandon Pentz, et al.
The Journal of Pathology. Clinical Research
|
August 28, 2020
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation
Paul G Kemps, Konnie M Hebeda, Steven T Pals, et al.
Blood
|
September 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, et al.
Cancer Immunology Research
|
November 12, 2020
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies
Iris de Weerdt, Roeland Lameris, George L Scheffer, et al.
Page
of 22